Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Jun 28;39(6):BSR20182240.
doi: 10.1042/BSR20182240. Print 2019 Jun 28.

Investigation of leptin receptor rs1137101 G>A polymorphism with cancer risk: evidence from 35936 subjects

Guoxiang Rong  1 , Weifeng Tang  2 , Yafeng Wang  3 , Hao Qiu  4 , Shuchen Chen  5
Affiliations
Meta-Analysis

Investigation of leptin receptor rs1137101 G>A polymorphism with cancer risk: evidence from 35936 subjects

Guoxiang Rong et al. Biosci Rep. .

Abstract

Leptin receptor (LEPR) signaling may be involved in promoting angiogenesis and proliferation, inhibiting apoptosis and playing a vital role in the progression of carcinogenesis. A number of studies have focused on the association of LEPR rs1137101 variants with susceptibility of cancer, however, the observed results were controversial. We searched literature on the relationship of LEPR rs1137101 G>A polymorphism with cancer risk by using PubMed and Embase databases, covering all publications up to 14 October 2018. In total, 44 case-control studies with 35,936 subjects were included. After combining all eligible studies, we identified null relationship between LEPR gene rs1137101 G>A polymorphism and overall cancer risk [A vs. G: odds ratio (OR ) = 0.97, 95% confidence interval (CI ) = 0.89-1.06, P = 0.547; AA vs. GG: OR = 0.93, 95% CI = 0.78-1.13, P = 0.476; AA/GA vs. GG: OR = 0.99, 95% CI = 0.91-1.09, P= 0.890 and AA vs. GA/GG: OR = 0.92, 95% CI = 0.82-1.04, P= 0.198]. However, in a subgroup analysis, there was an increased susceptibility of oral and oropharyngeal cancer in AA vs. GA/GG genetic model (OR, 1.83; 95% CI, 1.01-3.33; P=0.048). Considering the limited participants were included, the findings might be underpowered. Sensitivity analysis identified that any independent study omitted did not materially influence the pooled ORs and CIs. The results of publication bias detection showed that there was no evidence of bias. In summary, this analysis indicates that no significant association of cancer risk was identified to be correlated with rs1137101 G>A variants, even in stratified analyses.

Keywords: cancer; energy; leptin; polymorphism; receptor; risk.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no competing interests associated with the manuscript.

Figures

Figure 1
Figure 1. Flow diagram of the meta–analysis of the association between LEPR rs1137101 G>A polymorphism and cancer risk
Figure 2
Figure 2. Meta-analysis of the association between LEPR rs1137101 G>A polymorphism and cancer risk (AA/GA vs. GG, random–effects model)
Figure 3
Figure 3. Meta-analysis of the association between LEPR rs1137101 G>A polymorphism and cancer risk (AA vs. GG, random–effects model)
Figure 4
Figure 4. Meta-analysis of the association between LEPR rs1137101 G>A polymorphism and cancer risk (AA vs. GG/GA, random–effects model)
Figure 5
Figure 5. Meta-analysis of the association between LEPR rs1137101 G>A polymorphism and cancer risk (A vs. G, random–effects model)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bray F., Ferlay J., Soerjomataram I.. et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–42410.3322/caac.21492 - DOI - PubMed
    1. Suarez A.L. (2018) Burden of cancer attributable to obesity, type 2 diabetes and associated risk factors. Metabolism 92, 136–14610.1016/j.metabol.2018.10.013 - DOI - PubMed
    1. Spyrou N., Avgerinos K.I., Mantzoros C.S.. et al. (2018) Classic and novel adipocytokines at the intersection of obesity and cancer: diagnostic and therapeutic strategies. Curr. Obes. Rep. 7, 260–27510.1007/s13679-018-0318-7 - DOI - PubMed
    1. Hicks D.F., Bakst R., Doucette J.. et al. (2018) Impact of obesity on outcomes for patients with head and neck cancer. Oral Oncol. 83, 11–1710.1016/j.oraloncology.2018.05.027 - DOI - PubMed
    1. Chadid S., Singer M.R., Kreger B.E.. et al. (2018) Midlife weight gain is a risk factor for obesity-related cancer. Br. J. Cancer 118, 1665–1671, PubMed Central PMCID: PMC600844110.1038/s41416-018-0106-x - DOI - PMC - PubMed

Publication types